Status:
RECRUITING
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
Lead Sponsor:
Bayer
Conditions:
Chronic Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
19+ years
Brief Summary
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction...
Eligibility Criteria
Inclusion
- Adult aged 19 years or older
- Chronic HF (NYHA functional class II, III, or IV) Reduced left ventricular ejection fraction (\< 45%) within 12 months before enrollment
- Worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months)
- Participants who have been prescribed Verquvo (Vericiguat) as per locally approved label and didn't receive Verquvo (Vericiguat) therapy previously.
- Written informed consent from subject or legal representative; assent from subject when appropriate
Exclusion
- Contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy)
- Participants participating in an investigational program with interventions outside of routine clinical practice
Key Trial Info
Start Date :
November 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2027
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06148935
Start Date
November 30 2023
End Date
September 30 2027
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, South Korea